Litcius/Paper detail

Sequelae following infantile haemangiomas treated with propranolol

Eulàlia Baselga, May El Hachem, Andrea Diociaiuti, Claudia Carnevale, Camila Downey, Esther Roé, Patricia Mascaro, Iria Neri, Miriam Leuzzi, José Bernabéu‐Wittel, M.T. Monserrat-García, Alejandro Ortiz‐Prieto, Antonio Torrelo, Nicole Knöpfel, Nadia Vercellino, Francesca Manunza, Teresa Oranges, Andrea Bassi, María Antonia González-Enseñat, Asunción Vicente, Ignasi Gich, L. Puig

2021European Journal of Dermatology11 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Oral propranolol accelerates the involution of infantile haemangiomas (IHs). However, it is not clear whether IHs treated with oral propranolol are associated with fewer sequelae than when left untreated. OBJECTIVES: To quantify and describe sequelae associated with IHs treated with oral propranolol, and to explore whether treated IHs are associated with fewer sequelae than untreated IHs. MATERIALS & METHODS: This multicentre, retrospective, cohort study included patients with IH treated with oral propranolol ≥2 mg/kg for at least six months, with photographic images available at baseline and at age 4-5 years. A historical comparison cohort comprised 185 patients with untreated IHs. Main outcomes/measures were: IH features, treatment characteristics and type/degree of sequelae. RESULTS: Oral propranolol, most commonly at 2 mg/kg/day (mean duration: nine months), was initiated in 171 patients (mean age: 6.02 months). After treatment, 125 of 171 (73.1%) IHs were associated with no/minimal sequelae. The most common sequelae were telangiectasia (78%), fibrofatty tissue (37%) and anetodermic skin (28%). Deep IHs were associated with significantly fewer sequelae than other subtypes. Ulceration appeared to increase the likelihood of severe sequelae. IHs with a stepped border was associated with more severe sequelae than those with a progressive border (44% versus 27%, p < 0.05). Treated IHs resolved without sequelae or were associated with a sequela that did not need correction in 27.7% more cases than untreated IHs (RR: 1.61; p < 0.001). CONCLUSION: Among IHs treated with oral propranolol, 73% resolved without, or were associated with minimal sequelae. Deep IHs were associated fewer sequelae than other subtypes. Oral propranolol decreased the likelihood of IH sequelae requiring correction.

Topics & Concepts

MedicinePropranololSequelaCohortDiscontinuationRetrospective cohort studySurgeryInvolution (esoterism)TelangiectasiaCohort studyInternal medicinePoliticsPolitical scienceLawVascular Malformations and HemangiomasVascular Anomalies and TreatmentsAutoimmune and Inflammatory Disorders Research